Difference between revisions of "Conflict of interest"
m |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
==Introduction== | ==Introduction== | ||
| − | With the September 2018 expose in the New York Times on | + | With the September 2018 expose in the New York Times on José Baselga, a leader in the field of breast oncology and medical oncology as a whole, public awareness of financial conflicts of interest in hematology/oncology is on the rise. Financial and other conflicts of interest are not new to biomedicine but can certainly diminish trust in the profession. We plan to develop this page as an archive of lay media and peer-reviewed literature covering the topic; it will be expanded over time. |
| − | + | ==Widespread problems with disclosure of COI== | |
| − | == | + | *12/8/2018: NYT: [https://www.nytimes.com/2018/12/08/health/medical-journals-conflicts-of-interest.html What These Medical Journals Don’t Reveal: Top Doctors’ Ties to Industry] |
| + | ==MSKCC and Paige.AI== | ||
| + | *9/20/2018: ProPublica: [https://www.propublica.org/article/sloan-kettering-cozy-deal-with-start-up-paige-ai-ignites-new-uproar Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar] | ||
| + | ==José Baselga controversy== | ||
*9/8/2018, NYT: [https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals] | *9/8/2018, NYT: [https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals] | ||
*9/13/2018, NYT: [https://www.nytimes.com/2018/09/13/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties] | *9/13/2018, NYT: [https://www.nytimes.com/2018/09/13/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties] | ||
*9/14/2018, NYT: [https://www.nytimes.com/2018/09/14/opinion/jose-baselga-research-disclosure-bias.html Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research] | *9/14/2018, NYT: [https://www.nytimes.com/2018/09/14/opinion/jose-baselga-research-disclosure-bias.html Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research] | ||
| + | *9/15/2018, NYT: [https://www.nytimes.com/2018/09/14/opinion/medicines-financial-contamination.html Medicine’s Financial Contamination] | ||
==What we are doing== | ==What we are doing== | ||
Latest revision as of 01:09, 9 December 2018
Introduction
With the September 2018 expose in the New York Times on José Baselga, a leader in the field of breast oncology and medical oncology as a whole, public awareness of financial conflicts of interest in hematology/oncology is on the rise. Financial and other conflicts of interest are not new to biomedicine but can certainly diminish trust in the profession. We plan to develop this page as an archive of lay media and peer-reviewed literature covering the topic; it will be expanded over time.
Widespread problems with disclosure of COI
MSKCC and Paige.AI
- 9/20/2018: ProPublica: Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar
José Baselga controversy
- 9/8/2018, NYT: Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals
- 9/13/2018, NYT: Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
- 9/14/2018, NYT: Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research
- 9/15/2018, NYT: Medicine’s Financial Contamination
What we are doing
HemOnc.org was founded with the goal of creating a freely available, comprehensive, centralized repository of chemotherapy drug and treatment regimens. From the beginning, our philosophy has been to remain ad-free, revenue-neutral, and an international community resource without paywalls or registration requirements. In the interests of transparency, we will be adding financial conflict of interest disclosures to our Editorial Board page. If you have other thoughts about how we can maximize transparency, please contact us at [email protected].